Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents

Sek Kwong Poon, Chih Ho Lai, Chi Sen Chang, Wei Yu Lin, Yun Chieh Chang, Hung Jung Wang, Pao Hsuan Lin, Hwai Jeng Lin, Wen Ching Wang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

During 1998-2004, a total of 218 Helicobacter pylori isolates were obtained from patients who were randomised to receive one of the following regimens in a medical centre in Taiwan: lansoprazole, amoxicillin and clarithromycin (LAC) therapy; or lansoprazole, metronidazole and clarithromycin (LMC) therapy. In the LMC group, resistance rates for metronidazole and clarithromycin reduced from 48.6% (1998-2000) to 20.4% (2001-2004) (P <0.05) and from 13.5% to 6.3% (P <0.05), respectively. Analysis of annual antimicrobial consumption found that metronidazole use was slowly decreased both in the total population and in gastrointestinal disease patients. The per-protocol analysis revealed a higher eradication rate for patients using LMC therapy in 2001-2004 (82.6% vs. 75.0%), whilst there was similar efficacy for LAC therapy (84.8% vs. 84.2%). This observation suggests an effective programme to control H. pylori antibiotic resistance and hence elevate its cure rate.

Original languageEnglish
Pages (from-to)162-165
Number of pages4
JournalInternational Journal of Antimicrobial Agents
Volume34
Issue number2
DOIs
Publication statusPublished - Aug 2009
Externally publishedYes

Fingerprint

Clarithromycin
Lansoprazole
Anti-Infective Agents
Taiwan
Helicobacter pylori
Metronidazole
Amoxicillin
Gastrointestinal Diseases
Therapeutics
Microbial Drug Resistance
Population

Keywords

  • Antimicrobial consumption
  • Antimicrobial policy
  • Antimicrobial resistance
  • Helicobacter pylori

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents. / Poon, Sek Kwong; Lai, Chih Ho; Chang, Chi Sen; Lin, Wei Yu; Chang, Yun Chieh; Wang, Hung Jung; Lin, Pao Hsuan; Lin, Hwai Jeng; Wang, Wen Ching.

In: International Journal of Antimicrobial Agents, Vol. 34, No. 2, 08.2009, p. 162-165.

Research output: Contribution to journalArticle

Poon, Sek Kwong ; Lai, Chih Ho ; Chang, Chi Sen ; Lin, Wei Yu ; Chang, Yun Chieh ; Wang, Hung Jung ; Lin, Pao Hsuan ; Lin, Hwai Jeng ; Wang, Wen Ching. / Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents. In: International Journal of Antimicrobial Agents. 2009 ; Vol. 34, No. 2. pp. 162-165.
@article{336f5c9f6290451c9dbc150826fe6ba9,
title = "Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents",
abstract = "During 1998-2004, a total of 218 Helicobacter pylori isolates were obtained from patients who were randomised to receive one of the following regimens in a medical centre in Taiwan: lansoprazole, amoxicillin and clarithromycin (LAC) therapy; or lansoprazole, metronidazole and clarithromycin (LMC) therapy. In the LMC group, resistance rates for metronidazole and clarithromycin reduced from 48.6{\%} (1998-2000) to 20.4{\%} (2001-2004) (P <0.05) and from 13.5{\%} to 6.3{\%} (P <0.05), respectively. Analysis of annual antimicrobial consumption found that metronidazole use was slowly decreased both in the total population and in gastrointestinal disease patients. The per-protocol analysis revealed a higher eradication rate for patients using LMC therapy in 2001-2004 (82.6{\%} vs. 75.0{\%}), whilst there was similar efficacy for LAC therapy (84.8{\%} vs. 84.2{\%}). This observation suggests an effective programme to control H. pylori antibiotic resistance and hence elevate its cure rate.",
keywords = "Antimicrobial consumption, Antimicrobial policy, Antimicrobial resistance, Helicobacter pylori",
author = "Poon, {Sek Kwong} and Lai, {Chih Ho} and Chang, {Chi Sen} and Lin, {Wei Yu} and Chang, {Yun Chieh} and Wang, {Hung Jung} and Lin, {Pao Hsuan} and Lin, {Hwai Jeng} and Wang, {Wen Ching}",
year = "2009",
month = "8",
doi = "10.1016/j.ijantimicag.2009.02.007",
language = "English",
volume = "34",
pages = "162--165",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents

AU - Poon, Sek Kwong

AU - Lai, Chih Ho

AU - Chang, Chi Sen

AU - Lin, Wei Yu

AU - Chang, Yun Chieh

AU - Wang, Hung Jung

AU - Lin, Pao Hsuan

AU - Lin, Hwai Jeng

AU - Wang, Wen Ching

PY - 2009/8

Y1 - 2009/8

N2 - During 1998-2004, a total of 218 Helicobacter pylori isolates were obtained from patients who were randomised to receive one of the following regimens in a medical centre in Taiwan: lansoprazole, amoxicillin and clarithromycin (LAC) therapy; or lansoprazole, metronidazole and clarithromycin (LMC) therapy. In the LMC group, resistance rates for metronidazole and clarithromycin reduced from 48.6% (1998-2000) to 20.4% (2001-2004) (P <0.05) and from 13.5% to 6.3% (P <0.05), respectively. Analysis of annual antimicrobial consumption found that metronidazole use was slowly decreased both in the total population and in gastrointestinal disease patients. The per-protocol analysis revealed a higher eradication rate for patients using LMC therapy in 2001-2004 (82.6% vs. 75.0%), whilst there was similar efficacy for LAC therapy (84.8% vs. 84.2%). This observation suggests an effective programme to control H. pylori antibiotic resistance and hence elevate its cure rate.

AB - During 1998-2004, a total of 218 Helicobacter pylori isolates were obtained from patients who were randomised to receive one of the following regimens in a medical centre in Taiwan: lansoprazole, amoxicillin and clarithromycin (LAC) therapy; or lansoprazole, metronidazole and clarithromycin (LMC) therapy. In the LMC group, resistance rates for metronidazole and clarithromycin reduced from 48.6% (1998-2000) to 20.4% (2001-2004) (P <0.05) and from 13.5% to 6.3% (P <0.05), respectively. Analysis of annual antimicrobial consumption found that metronidazole use was slowly decreased both in the total population and in gastrointestinal disease patients. The per-protocol analysis revealed a higher eradication rate for patients using LMC therapy in 2001-2004 (82.6% vs. 75.0%), whilst there was similar efficacy for LAC therapy (84.8% vs. 84.2%). This observation suggests an effective programme to control H. pylori antibiotic resistance and hence elevate its cure rate.

KW - Antimicrobial consumption

KW - Antimicrobial policy

KW - Antimicrobial resistance

KW - Helicobacter pylori

UR - http://www.scopus.com/inward/record.url?scp=67349100955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349100955&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2009.02.007

DO - 10.1016/j.ijantimicag.2009.02.007

M3 - Article

VL - 34

SP - 162

EP - 165

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -